ZEISS PALM MicroBeam IV module Rel 4.2

ZEISS PALM MicroBeam IV 模块 Rel 4.2

• 批准号: 8052425
• 负责人: Sashwati Roy
• 金额: $ 29.69万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-04-15 至 2012-10-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8052425
• 关键词: Academic Medical Centers; Admixture; Affect; Applications Grants; Area; Award; Biology; Cells; Child; Clinical Sciences; Clinical and Translational Science Awards; Commit; Communities; Core Facility; DNA; Development; Diagnostics Research; Direct Costs; Dissection; Equipment; Extramural Activities; Faculty; Funding; Future; Gene Expression; Germany; Goals; Heterogeneity; Housing; Institution; Lasers; Legal patent; Methodology; Methods; Microdissection; Minor; Molecular; Molecular Profiling; National Center for Research Resources; Ohio; Outcome; Pathology; Population; Productivity; Proteins; Proteomics; RNA; Request for Proposals; Research; Research Personnel; Research Project Grants; Resources; Sampling; Technology; Tissues; Translational Research; United States National Institutes of Health; Universities; indexing; instrument; instrumentation; novel; pressure; programs; response

DESCRIPTION (provided by applicant): This proposal requests NCRR support for the acquisition of state-of-the-art PALM MicroBEAM IV laser capture micro-dissection instrument (PALM MicroBeam) from Zeiss (P.A.L.M. Microlaser Technologies, Carl Zeiss Group, Bernried, Germany). This equipment would be the first laser capture equipment for shared use in the Ohio State University (OSU). The entire OSU or nearby Nationwide Children's do not have a Laser Capture Micro-dissection (LCM) core facility. The requested instrument will be housed in Laser Capture Molecular Core facilities (https://lcm.osu.edu/index.cfm) in the Ohio State University Medical Center (OSUMC). ). Space and relevant resources have been committed for the proposed core in response to faculty requests. In May, 2008 OSU was awarded the prestigious NIH Clinical and Translational Science Award (CTSA). LCM novel methodology development was a priority area in this award. The PI together with two other investigators was awarded research grant to develop proteomics and miR profiling methods from LCM samples. These methods are now ready for dissemination; OSU CTSA has announced matching funds for dissemination of methodology developed via Laser Capture Molecular Core to OSU investigators. The requested PALM MicroBeam has the patented laser microdissection and pressure catapulting (LMPC) technology. The molecular examination of pathologically altered cells and tissues at the DNA, RNA, and protein level has revolutionized research and diagnostics in pathology. However, the inherent heterogeneity of primary tissues with an admixture of various reactive cell populations can affect the outcome and interpretation of molecular studies. Particularly suited to study spatially resolved biology, LMPC enables the investigator to isolate samples of pure cell populations as small as single cells or even sub cellular fragments for further molecular profiling (gene expression, proteomics). The equipment is expected to directly enhance the productivity of a minimum of 14 (8 major users and 6 minor users) currently funded federal research grants totaling > $ 2.5 million in annual direct costs. The long term goals of the core facility are to provide diverse research community of OSUMC and affiliated research institutions with the latest LCM technology and applications. The funding of this instrumentation grant application for LCM will transform the capability of the federally funded research programs at the OSU, increasing their productivity and competitiveness for future extramural funding that can impact NIH and/or other extra mural funded research at OSU. PUBLIC HEALTH RELEVANCE: PALM MicroBeam IV is high-throughput laser microdissection (LCM) equipment. Using this technology, individual cells and specific regions can be captured from clinically relevant small tissue section for genomic and proteomic analyses. The technology is best suited and is essential for human health relevant translational research.

描述(由申请人提供)：本建议书请求NCRR支持从蔡司(德国伯恩里德的卡尔·蔡司集团的P.A.L.M.微激光技术公司)收购最先进的Palm MicroBeam IV激光捕获显微解剖仪器(Palm MicroBeam)。该设备将是俄亥俄州立大学(OSU)第一个共享使用的激光捕获设备。整个俄亥俄州立大学或附近的全国儿童中心都没有激光捕获显微解剖(LCM)的核心设施。所要求的仪器将被安置在俄亥俄州立大学医学中心的激光捕获分子核心设施(https://lcm.osu.edu/index.cfm))中。)。应教职员工的要求，已为拟议的核心提供了空间和相关资源。2008年5月，俄亥俄州立大学荣获著名的美国国立卫生研究院临床与翻译科学奖(CTSA)。LCM新方法开发是该奖项的优先领域。PI和另外两名研究人员一起获得了从LCM样本中开发蛋白质组学和miR图谱方法的研究经费。这些方法现在已经准备好传播；俄亥俄州立大学CTSA已经宣布为向俄亥俄州立大学的研究人员传播通过激光捕获分子核心开发的方法提供匹配资金。所要求的Palm微束具有专利的激光显微切割和压力弹射(LMPC)技术。在DNA、RNA和蛋白质水平上对病理改变的细胞和组织进行分子检测，使病理学的研究和诊断发生了革命性的变化。然而，原生组织固有的异质性与不同反应细胞群的混合物可能会影响分子研究的结果和解释。LMPC特别适合于研究空间分辨生物学，使研究人员能够分离小到单个细胞甚至亚细胞片段的纯细胞群体样本，以便进一步进行分子图谱(基因表达、蛋白质组学)。这些设备预计将直接提高至少14个(8个主要用户和6个次要用户)的生产率，目前联邦研究拨款每年直接成本总计250万美元。核心设施的长期目标是为OSUMC及其附属研究机构的不同研究社区提供最新的LCM技术和应用。LCM仪器拨款申请的资助将改变俄亥俄州立大学联邦资助研究项目的能力，提高它们在未来可能影响NIH和/或OSU其他壁画资助研究的外部资金方面的生产力和竞争力。 公共卫生相关性：Palm MicroBeam IV是高通量激光显微解剖(LCM)设备。利用这项技术，可以从临床相关的小组织切片中捕获单个细胞和特定区域，用于基因组和蛋白质组分析。这项技术最适合人类健康相关的翻译研究，而且是必不可少的。